Robert James Hemmings
Overview
Explore the profile of Robert James Hemmings including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Collignon O, Gartner C, Haidich A, James Hemmings R, Hofner B, Petavy F, et al.
Clin Pharmacol Ther
. 2020 Feb;
107(5):1059-1067.
PMID: 32017052
Master protocols have received a growing interest during the last years. By assigning patients to specific substudies, they aim at targeting and accelerating clinical development. Given their complexity, basket, umbrella,...
2.
Collignon O, Koenig F, Koch A, James Hemmings R, Petavy F, Saint-Raymond A, et al.
Trials
. 2018 Nov;
19(1):642.
PMID: 30454061
Background: In recent years, experience on the application of adaptive designs in confirmatory clinical trials has accumulated. Although planning such trials comes at the cost of additional operational complexity, adaptive...
3.
Elsasser A, Regnstrom J, Vetter T, Koenig F, James Hemmings R, Greco M, et al.
Trials
. 2014 Oct;
15:383.
PMID: 25278265
Background: Since the first methodological publications on adaptive study design approaches in the 1990s, the application of these approaches in drug development has raised increasing interest among academia, industry and...
4.
Tzogani K, Nagercoil N, James Hemmings R, Samir B, Gardette J, Demolis P, et al.
Eur J Dermatol
. 2014 Aug;
24(4):457-63.
PMID: 25115145
Background: The European Commission has recently issued a marketing authorisation valid throughout the European Union for ingenol mebutate (Picato) in the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults....
5.
Gravanis I, Lopez A, James Hemmings R, Jimenez J, Garcia-Carbonero R, Gallego I, et al.
Oncologist
. 2013 Aug;
18(9):1032-42.
PMID: 23966222
On September 5, 2011, abiraterone was approved in the European Union in combination with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (CRPC) in adult men whose...
6.
Pean E, Demolis P, Moreau A, James Hemmings R, OConnor D, Brown D, et al.
Oncologist
. 2012 Apr;
17(4):543-9.
PMID: 22477727
On March 17, 2011 the European Commission issued a marketing authorization valid throughout the European Union for Jevtana® (Sanofi-Aventis, Paris, France) for the treatment of patients with hormone-refractory metastatic prostate...